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Antibiotic resistance of bacteria is commonly seen in
daily medical practice. Among the different types of
drug resistance, most microbiologists would agree
that multidrug-resistant Gram-negative bacteria pose
the greatest risk to human health because the speed of
increase of drug resistance in Gram-negative bacteria
is much faster than that in Gram-positive bacteria. In
addition, there are fewer effective new drugs devel-
oped specifically against Gram-negative bacteria.1–3
Escherichia coli and Klebsiella pneumoniae, belong-
ing to the Enterobacteriaceae, are 2 important and fre-
quently encountered pathogens in various nosocomial
and community-associated infections in humans. In
treating patients with Enterobacteriaceae infection, a
particular concern is the development of resistance to
the carbapenems, including imipenem, meropenem,
ertapenem and doripenem, because these drugs are
often the last available treatment options for infec-
tions due to multidrug-resistant Enterobacteriaceae.4
Metallo-β-lactamase is one of the carbapenemases that
are produced by multidrug-resistant Enterobacteriaceae.
Recently, the emergence of New Delhi metallo-β-
lactamase 1 (NDM-1)-positive Enterobacteriaceae has
been identified worldwide, and many cases had a his-
tory of traveling in India or Pakistan. These bacterial
isolates carry a new resistance mechanism that may
render most, if not all, currently used β-lactam antibi-
otics ineffective.5
The rapid increase of drug resistance in Enterobac-
teriaceae is mainly attributed to the genes located on
plasmids that can subsequently and quickly spread in
different bacteria species.6 Nowadays, frequent interna-
tional or intercontinental air travel and migration allow
bacterial plasmids to be transported rapidly between
countries.7 Intimate physical contact between asymp-
tomatic subjects further facilitates the transmission of
the bacteria. In this issue of the Journal of the Chinese
Medical Association,8 Wu et al describe a patient harbor-
ing NDM-1-positive Klebsiella pneumoniae. Although
he was initially a patient with gun-shot injury, the
pathogen was detected in his stool. He was clinically
asymptomatic and the presence of the bacteria was
considered to be due to intestinal colonization. There
has been intense debate on the outpatient management
of this patient after he was discharged from hospital.
A major concern is whether the NDM-1-producing
bacteria will transfer the plasmid to other bacteria in
the environment and generate new multidrug-resistant
bacteria. Close monitoring of this patient is therefore
mandatory to prevent a potential outbreak of the
infection in the community.
Without appropriate or powerful antibiotics as
weapons, what can we do about these “superbacteria”
once clinically significant infections occur? First, the
spread and potential pandemic resulting from the
NDM-1-producing Enterobacteriaceae deserve effec-
tive monitoring and preventive measures not only 
by individual countries, but also through interna-
tional collaboration. The invisible war between bacte-
ria and humans continues to be a major challenge,
and the story of superbacteria pandemics will repeat
itself again and again. Second, detailed epidemio-
logical, clinical and laboratory information should be
gathered and inspected in each potential outbreak. If
this emerging public health threat is ignored, the
medical community could encounter carbapenem-
resistant Enterobacteriaceae that will cause uncontrolled
community-acquired or nosocomial infections, result-
ing in inadequate treatment and death. Lastly, since the
invasion of NDM-1-positive bacteria to a certain com-
munity or country is inevitable, primary care physicians
and health care providers, public health personnel
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and clinical microbiologists should cooperate to find
the best solution to treat infected subjects. Standard
procedures for prevention and care of high-risk and
already-infected subjects should be established as
soon as possible to minimize the spread of infection,
reduce the health care costs, and avoid serious clinical
consequences.
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